Tuning ITAM multiplicity on T cell receptors can control potency and selectivity to ligand densityScience… T cell signaling at the single-cell level. The experimental data fit computational models predicting that increasing ITAM number influenced the… Continue reading
IFLScience |
Robots Are Growing Mini Human Organs From Stem Cells
IFLScience Welcome to the real Westworld. Scientists have designed an automated system that uses robots to create human mini-organs using stem cells. But don’t worry, giving robots the means to forge mini-organs won’t end in some reality-bending dystopia. Instead … Robots grow mini-organs from human stem cellsSpace Daily One step closer for kidney tissue engineeringphysicsworld.com |
Bloomberg |
Gene Therapies That Could Transform Diseases Get Easier FDA Path
Bloomberg Unlike traditional drugs, gene therapies are intended to be given once, transform the inner workings of the body and last for a lifetime. For regulators, the challenge is to find ways to get the new therapies to desperate patients while balancing the … FDA plans to speed path to approval for some gene therapies, starting with hemophiliaSTAT Gottlieb: FDA Prepping for Push of New Gene and Cell TherapiesRegulatory Focus Remarks by Commissioner Gottlieb to the Alliance for Regenerative Medicine’s Annual Board MeetingStreetInsider.com |
Triangle Business Journal |
Company recently acquired by Novartis bringing 200 jobs to Durham
Triangle Business Journal Bannockburn, Illinois-based gene therapy company AveXis is bringing 200 new jobs to Durham through a new $55 million manufacturing center, Gov. Roy Cooper’s office announced Tuesday. The clinical-stage company is focused on developing therapies … |
WRAL Tech Wire |
Illinois-based AveXis bringing $55M gene therapy factory, 200 jobs to Durham
WRAL Tech Wire RESEARCH TRIANGLE PARK – AveXis, an Illinois-based clinical-stage company developing gene therapies for neurological genetic diseases, is investing $55 million in a new Durham manufacturing facility that will create 200 jobs. It’s the latest in a … |